AIFA clarifies the simplified procedure for generics classification in class C
Last 15 October, the Italian Medicine Agency had announced the introduction of a new simplified price and reimbursement procedure for the classification of generics and biosimilars, i.e. the classification in class C (totally charged to patients) of drugs with reference product already classified in this class, as early as at authorization with no HTA sector or Committees assessment and with no preliminary classification in class Cnn.
After some months, the Agency has come back on this procedure to provide some clarifications, with special reference to the methods of application of the new procedure.
First of all, the Agency specified that this procedure applies to MA or line extension application submitted based on art. 10(1) (‘generic application’), art. 10(3) (‘hybrid application’) and art. 10(4) (‘biosimilar application’) of Directive 2001/83/EC, including the new pack sizes with MA released based on these articles with type II and I variations and parallel importation applications (AIP). On the other hand, generic/hybrid/biosimilar products with additional therapeutic indications compared to those of the reference product are excluded.
Moreover, the Agency specified the cases when the procedure is applied, starting from the assumption that ‘similar pack sizes’ means pack size having the same quantity of active substance, pharmaceutical form, route of administration, method of release and posology units. The procedure will apply to generic/hybrid/biosimilar products: i) with similar pack sizes to those of the reference product wholly classified in class C; ii) with non similar pack sizes to those of the reference product wholly classified in class C; iii) only with similar pack sizes to those of the reference product that are classified in class C where the reference product also has different pack sizes reimbursed by the NHS (class A/H).
In case of generic/hybrid/biosimilar products with one or more pack sizes that are similar to those of the reference product with one or more pack sizes that are similar to those of the reference product that are reimbursed by the NHS (class A/H), the previous procedure remains applicable.
Generic/hybrid/biosimilar products presenting only pack sizes that are different for dosage, pharmaceutical form, number of posology units, method of release compared to those of the reference product reimbursed by the NHS (class A/H) will be classified in class C(nn).
In case of a European reference product, the relevant generic/hybrid/biosimilar product will be classified in class C(nn).
In any case, the application of the procedure provides for some waivers, for instance if the originator is included in special price and reimbursement schemes, such as a registry and/or a MEA and/or if one or more indications are included in the list as per Law 648/96 (no therapeutic options). In these cases, the generic drugs shall follow the ordinary negotiation process, and be assessed by the Scientific Technical Commission and by the Price and Reimbursement Committee, even if a price alignment is proposed.
The new simplified procedure already applies as of the CTS meeting of February 2021. For parallel importation medicines applies as of March.
The new procedure does not concern previously authorized medicines.
Finally, the Agency specified that the new procedure is not retroactive and does not concern medicinal products previously authorized. Therefore any change of classification from C(nn) to C shall be submitted according the methods already used. MA and variation applications already discussed during previous meetings of the Scientific Technical Commission will also be unaffected by the new simplified procedure.
Written by: Maria Pia Felici
Foto di Ulrike Leone da Pixabay
Previous Post
Next Post

